Puma Biotechnology logo
Puma Biotechnology PBYI
$ 6.94 0.58%

Annual report 2025
added 02-26-2026

report update icon

Puma Biotechnology Gross Profit 2011-2026 | PBYI

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Puma Biotechnology

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - 235 M 216 M 22.1 M - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
235 M 22.1 M 158 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-40.6 M $ 4.5 0.45 % $ 862 M canadaCanada
Agenus Agenus
AGEN
-18.3 M $ 3.64 9.31 % $ 108 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
117 M $ 35.08 -0.36 % $ 2.03 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
190 M $ 1.39 0.36 % $ 357 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
5.51 M - 2.54 % $ 160 B franceFrance
Aligos Therapeutics Aligos Therapeutics
ALGS
-10.5 M $ 8.08 1.38 % $ 79.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
195 M $ 331.14 3.85 % $ 43.4 B usaUSA
Altimmune Altimmune
ALT
8.18 K $ 3.4 1.8 % $ 300 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
436 K $ 1.99 0.81 % $ 107 M usaUSA
Amgen Amgen
AMGN
19 B $ 344.03 -1.12 % $ 185 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
1.11 B $ 12.27 -1.68 % $ 3.85 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
103 M $ 14.99 1.28 % $ 220 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
143 M $ 73.8 -0.55 % $ 1.43 B usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-104 K $ 0.88 -5.16 % $ 4.8 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
32.9 M $ 4.12 -0.24 % $ 441 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
4.73 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
10 K - 1.93 % $ 17.4 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
9.54 M $ 8.14 1.31 % $ 223 M israelIsrael
Ardelyx Ardelyx
ARDX
4.68 M $ 5.99 0.84 % $ 1.44 B usaUSA
argenx SE argenx SE
ARGX
2.68 M $ 749.99 0.48 % $ 25 B niderlandNiderland
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
147 K $ 60.28 -1.23 % $ 8.06 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
79.1 K $ 29.51 1.72 % $ 331 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
177 K $ 3.62 1.82 % $ 8.71 B australiaAustralia